Showing 111-120 of 1614 results for "".
Eye on the Target: Navigating Ocular Challenges With ADC Cancer Therapies
https://modernod.com/cme/ophthalmology/eye-on-the-target-2421/33187/Specialists in eye care and oncology come together to discuss strategies to manage ocular toxicities associated with specific cancer drugs.Ophthalmic Ointment for DED Moving Toward NDA Submission
https://modernod.com/editorial-series/significant-findings/ophthalmic-ointment-for-ded-moving-toward-nda-submission/49220/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuThrough the Eye to the Spine
https://modernod.com/articles/significant-findings/through-the-eye-to-the-spine/37838/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatThe State of Optometry’s Financial Health
https://modernod.com/topics/business/the-state-of-optometrys-financial-health/38792/Five takeaways from the largest income survey conducted in optometry.What’s New in Contact Lenses
https://modernod.com/topics/contact-lenses/whats-new-in-contact-lenses-1/38238/A look at developments over the past year.Build the Perfect Ocular Aesthetics Team
https://modernod.com/topics/business/build-the-perfect-ocular-aesthetics-team/39201/Collaboration with dermatologists can address patient needs and ensure comprehensive treatment.The Trouble With the Term “ECP”
https://modernod.com/mod-issues/2025-mar-apr/the-trouble-with-the-term-ecp/38943/Is this really the best way to refer to eye doctors?Why Now Is a Good Time to Buy a Private Practice
https://modernod.com/topics/business/why-now-is-a-good-time-to-buy-a-private-practice/38889/Early career ODs may want to consider taking advantage of a favorable buying market.Aldeyra Resubmits NDA for DED Drug Reproxalap
https://modernod.com/podcasts/eyewire-news-the-podcast/aldeyra-resubmits-nda-for-ded-drug-reproxalap/37053/Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.Two Partnerships Formed to Advance Glaucoma Treatments
https://modernod.com/podcasts/eyewire-news-the-podcast/two-partnerships-formed-to-advance-glaucoma-treatments/37051/Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system.